A new study in Nature reveals that patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine, researchers have found.

A new national study led by Trisha Amboree, Ph.D., at MUSC Hollings Cancer Center and Jane Montealegre, Ph.D., at MD Anderson Cancer Center highlights the untapped potential of federally qualified health centers (FQHCs) to close cervical cancer screening gaps. Published in JAMA Network Open, the research found that if FQHCs met national screening goals, they could reach nearly 2 million additional women—many in rural or low-income areas—and save thousands of lives. Because FQHCs serve patients who often face barriers to care, strengthening screening programs there could be one of the most direct and equitable ways to prevent cervical cancer. As Amboree put it, “We should be investing more, not less, in these community clinics. Cervical cancer could be a disease of the past if we do.”

The Mount Sinai Tisch Cancer Center (TCC) has been named a “Comprehensive Cancer Center” by the National Cancer Institute (NCI), the highest designation awarded to cancer centers in the United States. This recognition places Mount Sinai among the top one percent of cancer centers nationwide and affirms the breadth and depth of its cancer research, clinical excellence, and commitment to health equity. The designation also brings more than $3 million annually to support Mount Sinai’s research and innovation.

BUFFALO, NY — October 22, 2025 — A new case report was published in Volume 12 of Oncoscience on October 6, 2025, titled “A peculiar case of primary lymphoma of pancreas: A rare presentation of Hodgkin lymphoma.”

Cervical cancer, one of the most preventable yet lethal malignancies among women, continues to threaten lives globally due to unequal access to quality screening and diagnosis.

Corewell Health physicians are researching cancer treatment advancements with a new, nearly $2.2 million grant from the National Institutes of Health. The four-year grant will help doctors potentially bring a type of proton beam technology, called dynamic SPArc (Spot-Scanning Proton Arc), into everyday patient care.

Colorectal cancer is one of the most common tumours among people over the age of 50. Although it is known to develop from small lesions or polyps, its exact causes are unknown — only a few risk factors are known — and it is usually treated with surgery, chemotherapy and radiotherapy, or biological therapies. Now, a study by the University of Barcelona reveals that the combination of palbociclib and telaglenastat, two drugs with complementary actions, could help improve the clinical treatment of this type of cancer, the third most common worldwide.